Business Description
KalVista Pharmaceuticals Inc
NAICS : 325411
SIC : 2834
ISIN : US4834971032
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.15 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -20.5 | |||||
3-Year EPS without NRI Growth Rate | -27.2 | |||||
3-Year FCF Growth Rate | -2.6 | |||||
3-Year Book Growth Rate | 0.1 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64.66 | |||||
9-Day RSI | 60.41 | |||||
14-Day RSI | 55.25 | |||||
6-1 Month Momentum % | 47.83 | |||||
12-1 Month Momentum % | 22.61 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.44 | |||||
Quick Ratio | 5.44 | |||||
Cash Ratio | 3.95 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.2 | |||||
Shareholder Yield % | 0.15 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -78.73 | |||||
ROA % | -67.71 | |||||
ROIC % | -495.93 | |||||
ROC (Joel Greenblatt) % | -1199.75 | |||||
ROCE % | -85.67 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 4.72 | |||||
Price-to-Tangible-Book | 4.72 | |||||
EV-to-EBIT | -3.57 | |||||
EV-to-EBITDA | -3.59 | |||||
EV-to-Forward-Revenue | 42.65 | |||||
EV-to-FCF | -4.55 | |||||
Price-to-Net-Current-Asset-Value | 5.3 | |||||
Price-to-Net-Cash | 8.33 | |||||
Earnings Yield (Greenblatt) % | -28.01 | |||||
FCF Yield % | -19.06 |